Date | May 2011 | Marks available | 3 | Reference code | 11M.3.SL.TZ2.17 |
Level | Standard level | Paper | Paper 3 | Time zone | Time zone 2 |
Command term | Describe | Question number | 17 | Adapted from | N/A |
Question
Describe the use of viral vectors in gene therapy.
Markscheme
gene therapy involves replacing defective genes;
desired gene is inserted into the viral genome;
viruses can be modified to infect only target cells and not self-replicate / modified for safe use;
somatic cells are removed (for receiving the new genes);
the desired gene is introduced into the target/somatic cells;
altered cells are returned to the patient for expression of the gene;
properly described verified example e.g. replacement of gene for production of ADA in SCID / introduction of gene/RPE65 (in retina) to restore vision in inherited blindness (LCA) / replacement of factor IX/blood clotting factor gene in hemophilic patients;
Examiners report
N/A